Fig. 2: AURKA inhibitors induce synthetic lethality in RB1−/− lung cancer in vivo. | Nature Communications

Fig. 2: AURKA inhibitors induce synthetic lethality in RB1−/− lung cancer in vivo.

From: Synthetic lethality of RB1 and aurora A is driven by stathmin-mediated disruption of microtubule dynamics

Fig. 2

Tumor growth curve of the A549 RB1+/+ (a) and RB1−/− (b) lung cancer xenografts in mice treated with ENMD-2076. c Endpoint weight measurement of tumors isolated from the nude mice bearing A549 RB1+/+ and RB1−/− lung cancer xenografts. Tumor growth curve of the HCC827 RB1+/+ (d) and RB1−/− (e) lung cancer xenografts in mice treated with ENMD-2076. f Endpoint weight measurement of tumors isolated from nude mice bearing HCC827 RB1+/+ and RB1−/− lung cancer xenografts. Tumor growth curve of the HCC827 RB1+/+ (g) and RB1−/− (h) lung cancer xenografts in mice treated with alisertib. i Endpoint weight measurement of tumors isolated from nude mice bearing HCC827 RB1+/+ and RB1−/− lung cancer xenografts. Data are presented as mean ± SD (n = 6 independent animals per group). *P < 0.05; **P < 0.01 vs no treatment control, determined using two-sided Student’s t test. j Representative images of vehicle-treated and ENMD-2076-treated nude mice bearing A549 RB1+/+ and RB1−/− lung cancer xenografts. Tumor areas are indicated with dotted lines. k Western blot analyses of expression levels of RB1, cleaved caspase3, and α-tubulin in the tumor tissues. GAPDH was used as a loading control.

Back to article page